InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,282.00
(
-0.27%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.14
(
-0.25%
)
Bitcoin
63,158.60
(
0.33%
)
Post# of 2969
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

nymostwanted

Send PM Follow Ignore
Followers 31
Posts 2053
Boards Moderated 0
Alias Born 02/14/2014

nymostwanted

Re: None

Tuesday, 01/10/2017 8:35:58 AM

Tuesday, January 10, 2017 8:35:58 AM

Post# of 2969
SAN DIEGO and VANCOUVER, British Columbia, May 12, 2016 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that it has engaged Oppenheimer & Co. Inc. as its financial advisor to assist with evaluation of strategic alternatives to advance the development of topsalysin and enhance shareholder value, including potential partnering arrangements, financings or a strategic transaction.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up